CalciMedica, Inc. (CALC) Research
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Market snapshot
- Symbol
- CALC
- Price
- $0.76
- Day change
- -10.07%
- Market cap
- $11.9M
- P/E ratio
- -0.58x
- 52-week range
- 0.461-7.2
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $266
Peer companies
Recent insider activity
- Bardin Stephen — A-Award (67728 shares) on 2025-04-05
- Hebbar Sudarshan — A-Award (91173 shares) on 2025-04-05
- Roberts Eric W — A-Award (83358 shares) on 2025-04-05
- Dunn Michael J. — A-Award (65124 shares) on 2025-04-05
- Stauderman Kenneth A. — A-Award (65124 shares) on 2025-04-05
Open CalciMedica, Inc. (CALC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.